Neion Bio Emerges from Stealth with $11M to Build Biologics Through Egg-Based Manufacturing

Neion Bio just stepped out of stealth with about $11M in financing, and it is not chasing the same old stainless steel dream every other biotech has been polishing for decades. This is New York City grit meeting biology with a twist you can’t unsee once it clicks. Caffeinated Capital led the charge across both pre seed and seed, with Basis Set Ventures and Haystack VC in the mix. That investor lineup reads like a group that knows when something smells different in the lab and in the market.

Demetrios Kellari and Sam Levin are not playing small ball here. Demetrios Kellari, Co Founder and CEO, comes out of systems thinking and real world execution. Sam Levin, PhD, Co Founder and CTO, brings the kind of scientific depth that does not need to raise its voice to be heard. Alongside them, Sven Bocklandt, PhD, Chief Scientific Officer, and Ming Li, President, Commercial Operations round out a team that understands both the molecule and the market. You do not get that combination by accident.

Now the part that makes people lean in a little closer. Neion Bio is building its Raptor platform around egg based biomanufacturing. Not metaphorically. Literally. Genetically engineered chickens producing recombinant biologics inside eggs. Monoclonal antibodies without the billion dollar bioreactor ego. It sounds like a punchline until you realize the math might actually work. Lower capital intensity, simpler infrastructure, and a path toward localized production that does not depend on massive facilities humming in the background.

They did not just raise capital and call it a day either. There is already a co development and supply agreement in place with a major global pharmaceutical company covering up to 3 monoclonal antibodies. Upfront payments, milestones, profit sharing. Real signals, not theoretical slides. When a platform company pairs funding with a commercial partner this early, it tells you the story has already made it out of the lab and into someone else’s P and L.

The takeaway is not that eggs are the future. The takeaway is that Neion Bio questioned a default the industry stopped questioning. Chinese hamster ovary cells have been the standard because they worked, not because they were perfect. Demetrios Kellari and Sam Levin asked a better question and found a stranger answer that might just scale.

Congratulations to Demetrios Kellari, Sam Levin, and the entire Neion Bio team. And credit to Caffeinated Capital, Basis Set Ventures, and Haystack VC for leaning into something that sounds a little crazy until it starts making a lot of sense.